A well-executed TPP serves as the strategic roadmap for a drug development program. It is an essential foundational document that aligns internal goals and facilitates productive interactions with regulatory agencies.

Keystone Biologics Advisory collaborates closely with clients to architect the TPP. Through in-depth consultation, we help determine the minimal and preferred acceptance criteria for your medicinal product, ensuring every stage of development is driven by the desired clinical and commercial outcome.

Strategic FDA Submissions and Authoring
Keystone Biologics Advisory provides end-to-end support for FDA regulatory submissions, ensuring technical data is translated into a compelling and compliant narrative. We specialize in authoring and reviewing the Module 3 (CMC) sections for pre-IND meetings, IND applications, and BLA submissions.

Pre-IND Engagement
Early, strategic engagement with the FDA is critical to de-risking your development program. We provide expert guidance through the entire pre-IND process:

• Strategic Advising: Developing a targeted regulatory strategy and identifying critical questions for the agency.

• Document Authoring: Preparing the pre-IND meeting request and comprehensive briefing book.

• Agency Interaction: Providing high-level support and attendance during FDA meetings to ensure productive dialogue.

IND and BLA Submissions
We navigate the complexities of Module 3 to build robust, phase-appropriate dossiers that align with the latest 2026 FDA flexible framework.

• Regulatory Readiness: Conducting comprehensive gap analyses of your CMC documentation to identify and remediate risks before submission.

• Technical Authoring: Full authoring of manufacturing processes, analytical controls, and risk-mitigation strategies.

• Lifecycle Strategy: Proposing regulatory pathways that facilitate a smooth transition from IND-stage development to final BLA licensure.

Our goal is to facilitate timely, strategic engagement with the FDA—positioning your program for successful clinical initiation and BLA approval.

Keystone Biologics Advisory provides targeted CMC guidance to de-risk development and ensure your program is positioned for regulatory success. Our core service offerings include:

• CMC Drug Development Plans
  Developing integrated roadmaps that align technical milestones with regulatory expectations from early phase through to commercialization.

• CMC Readiness Assessments for First-in-Human (FIH)
  Conducting deep-dive evaluations to ensure manufacturing, quality, and safety data meet the threshold for clinical initiation.

• CMC Gap Analysis for BLA
  Identifying and remediating technical and documentation gaps in preparation for the BLA.

• Comparability Exercises
  Designing robust comparability protocols to bridge manufacturing changes and scale-up throughout the product lifecycle.

• Control Strategy and Specifications Development
  Establishing phase-appropriate analytical controls and scientifically justified specifications that meet latest FDA standards.

• Stability Protocols and Data Review
  Providing expert review of stability programs to ensure data integrity and to support shelf-life justifications for clinical and commercial products.

Keystone Biologics Advisory works with clients to prepare a FDA regulatory strategy to facilitate the successful execution of the drug development program. We view FDA designations as more than just regulatory milestones—they are strategic levers.

We bridge the gap between regulatory status and technical execution, ensuring your manufacturing strategy is as fast and flexible as your clinical pathway.